13 citations
,
January 2010 in “Immunopharmacology and immunotoxicology” Diphencyprone increases Bcl-2 protein in patients with hair regrowth from alopecia areata.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
Letrozole combined with Cabergoline improves ovulation and pregnancy rates in women with PCOS and high prolactin levels compared to Letrozole alone.
November 2025 in “Figshare” Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
2 citations
,
October 1990 in “The Lancet” Some people have a genetic variation that makes them less effective at breaking down drugs.
1461 citations
,
March 2004 in “Annals of oncology” Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
January 2016 in “Surgical and Cosmetic Dermatology”
June 2020 in “Journal of Investigative Dermatology” More research with diverse participants is needed to determine the effectiveness of photobiomodulation devices for hair loss treatment.
1 citations
,
July 2025 in “Functional Foods in Health and Disease” CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
8 citations
,
January 2016 in “Annals of Dermatology” A complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide may help increase hair count in male pattern hair loss without side effects.
The study aims to find the best PRP dose for treating moderate carpal tunnel syndrome.
February 2024 in “Journal of Cosmetic Dermatology” Using a laser with bimatoprost solution works better for hair regrowth in alopecia areata than bimatoprost alone.
Platelet-rich plasma treatment significantly improved hair density and regrowth in both men and women suffering from pattern hair loss, with even better results when combined with certain medications.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
February 2014 in “Revista Argentina de Cardiología” Androgens may increase arrhythmias in Brugada Syndrome, while Finasteride could reduce them.
April 2018 in “Journal of Investigative Dermatology” The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
December 2025 in “Actas Dermo-Sifiliográficas” Bicalutamide may improve hair growth in postmenopausal women with mild side effects.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.
14 citations
,
January 2015 in “Annals of dermatology/Annals of Dermatology” Corticosteroid pulse therapy is more effective for severe alopecia areata than combination therapy.
1 citations
,
January 1995 in “Yakubutsu dōtai” April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.